CheckMate 649: Additional Analysis From the Phase III Trial of First-line Nivolumab + CT vs CT for Advanced Gastroesophageal Cancers

June 4-8, 2021; Online at https://conferences.asco.org/am
In previously untreated patients with advanced gastroesophageal cancers, nivolumab plus chemotherapy significantly prolonged OS and PFS vs chemotherapy alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 462 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Gain clinical insights quickly with this short slideset from Clinical Care Options (CCO) on key actionable biomarkers for GI cancers

David H. Ilson, MD, PhD John L. Marshall, MD Eric Van Cutsem, MD, PhD Released: July 23, 2021

From Clinical Care Options (CCO), video of pharmacist discussion of recently approved agents targeting HER2 and TROP2 for metastatic cancers

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Allison Butts, PharmD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 20, 2021 Expired: July 19, 2022

Slides from Clinical Care Options (CCO) on histology-agnostic biomarker testing to guide therapy for gastrointestinal cancer

John L. Marshall, MD Released: July 15, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and gastroesophageal cancers

David H. Ilson, MD, PhD Released: July 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue